Shares of Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) dropped 7.2% during mid-day trading on Tuesday . The company traded as low as $6.22 and last traded at $6.22. Approximately 404 shares traded hands during trading, a decline of 76% from the average daily volume of 1,696 shares. The stock had previously closed at $6.70.
Silence Therapeutics Stock Performance
The stock has a 50-day simple moving average of $6.54 and a 200-day simple moving average of $7.20.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Further Reading
- Five stocks we like better than Silence Therapeutics
- Market Cap Calculator: How to Calculate Market Cap
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 Fintech Stocks With Good 2021 Prospects
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What Makes a Stock a Good Dividend Stock?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
